MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Closed

SectorHealthcare

2.68 -1.47

Overview

Share price change

24h

Current

Min

2.67

Max

2.73

Key metrics

By Trading Economics

Income

-5.9M

247K

Sales

5.1M

62M

Profit margin

0.395

Employees

181

EBITDA

-6.1M

7.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+156.41% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-162M

726M

Previous open

4.15

Previous close

2.68

News Sentiment

By Acuity

94%

6%

356 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Sept 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 Sept 2025, 23:43 UTC

Hot Stocks

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 Sept 2025, 23:12 UTC

Earnings

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 Sept 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 Sept 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Lifeway Foods, Danone Agree to Stay Litigation

30 Sept 2025, 21:17 UTC

Earnings

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 Sept 2025, 20:47 UTC

Earnings

Nike 1Q Sales Rise as Turnaround Progresses

30 Sept 2025, 23:45 UTC

Market Talk

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 Sept 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 Sept 2025, 23:26 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 Sept 2025, 23:26 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 Sept 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 Sept 2025, 23:24 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 Sept 2025, 23:24 UTC

Acquisitions, Mergers, Takeovers

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 Sept 2025, 22:54 UTC

Market Talk

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 Sept 2025, 22:38 UTC

Earnings

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 Sept 2025, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 Sept 2025, 22:32 UTC

Market Talk

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 Sept 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 Sept 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 Sept 2025, 21:02 UTC

Earnings

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 Sept 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 Sept 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

30 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 Sept 2025, 20:28 UTC

Earnings

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 Sept 2025, 20:22 UTC

Earnings

Nike 1Q North America Revenue $5.02B >NKE

30 Sept 2025, 20:22 UTC

Earnings

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 Sept 2025, 20:22 UTC

Earnings

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 Sept 2025, 20:22 UTC

Earnings

Nike 1Q Greater China Revenue $1.51B >NKE

30 Sept 2025, 20:19 UTC

Earnings

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Peer Comparison

Price change

Akebia Therapeutics Inc Forecast

Price Target

By TipRanks

156.41% upside

12 Months Forecast

Average 7 USD  156.41%

High 8 USD

Low 6 USD

Based on 3 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.345 / N/ASupport & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

356 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat